Glycoera using megaround for precision approach to immunology

With an approach to depleting autoantibodies that’s designed to be more precise than current treatments, Glycoera has drawn a $130 million series B round to take its extracellular protein degrader program into the clinic.

Finding modalities to fully, durably and specifically deplete pathogenic autoantibodies has been challenging. Glycoera is going after IgG4-driven autoimmune diseases. The IgG4 subclass represents less than 5% of the IgG pool, yet current treatments deplete all the subclasses. ...